The aim of this study is to evaluate the effect off Granulocyte Colony Stimulating Factor (GCSF) in the treatment of Amyotrophic Lateral Sclerosis (ALS) patients.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
40
Iranian Neurology Research Center of Tehran University of Medical Sciences
Tehran, Tehran Province, Iran
patient's function
based on revised ALS Functional Rating scale (ALSFRS-r)
Time frame: one year
mobilizing bone marrow stem cells
based on cluster of differentiation 34 (CD34) and white blood cell (WBC) counting
Time frame: 1 year
amplitude of compound muscle action potential in ulnar and peroneal nerve
based on compound muscle action potential (CMAP) measured in nerve conduction study
Time frame: 1 year
quality of life
based on Amyotrophic Lateral Sclerosis Assessment Questionnaire (ALSAQ40)
Time frame: 1 year
muscle power
based on Muscle Manual Test (MMT)
Time frame: 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.